At the news
? MIXEDIMPACT 6/10 8-K filed Feb 26, 2026 at 07:10 ET
Kymera Therapeutics reported financial results for Q4 and full year 2025, highlighted by a $692 million equity raise, pipeline progress including initiation of Phase 2b trials for KT-621 in atopic dermatitis and asthma, and a new Chief Development Officer appointment. The company ended 2025 with $1.6 billion in cash, providing runway into 2029.
- Collaboration revenue declined 16.7% YoY to $39.2 million in 2025
- R&D expenses increased 31.8% YoY to $316.6 million in 2025
- Net loss widened to $311.4 million in 2025 from $223.9 million in 2024
- Completed $692 million equity offering in December 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access